Oncogenic K-Ras segregates at spatially distinct plasma membrane signaling platforms according to its phosphorylation status by Barceló, Carles et al.
1 
 
Oncogenic K-Ras segregates at spatially distinct plasma membrane signaling 
platforms according to its phosphorylation status 
Carles Barceló1, Noelia Paco1, Alison J. Beckett2, Blanca Alvarez-Moya1, Eduard 
Garrido1, Mariona Gelabert1, Francesc Tebar1, Montserrat Jaumot1, Ian Prior2 and Neus 
Agell1* 
 
1Departament de Biologia Cel·lular, Immunologia i Neurociències, Institut 
d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Facultat de Medicina. 
Universitat de Barcelona, C/ Casanova 143, 08036 Barcelona, Spain 
2 Physiological Laboratory, Department of Molecular and Cellular Physiology, Institute 
of Translational Research, University of Liverpool, Crown St., Liverpool L69 3BX, UK 
 
Running title: K-Ras domains by phosphorylation 
Keywords: K-Ras, nanoclustres, Raf, PI3K, PKC, phosphorylation 
 
*Author for correspondence (neusagell@ub.edu)
© 2013. Published by The Company of Biologists Ltd.
Jo
ur
na
l o
f C
el
l S
ci
en
ce
A
cc
ep
te
d 
m
an
us
cr
ip
t
 JCS Advance Online Article. Posted on 13 August 2013
2 
 
 
 
 
 
Summary 
Activating mutations in the K-Ras small GTPase are extensively found in human 
tumors. Although these mutations induced the generation of a constitutively GTP-
loaded, active form of K-Ras, phosphorylation at Ser181 within the C-terminal 
hypervariable region is able to modulate oncogenic K-Ras function without affecting 
the in vitro affinity for its effector Raf-1. In striking contrast, K-Ras phosphorylated at 
Ser181 showed an increased interaction with active form of Raf-1 and for PI3K (p110α) 
in cells. As most phosphorylated K-Ras is located at the plasma membrane, differential 
localization within this membrane according to the phosphorylation status was explored. 
Plasma membrane density gradient fractionation in the absence of detergents showed 
segregation of phosphomimetic and non-phosphorylatable K-Ras mutants (Ser181D and 
Ser181A, respectively). Moreover, immuno-electron-microscopy-statistics analysis 
showed that both phosphorylation mutants form distinct non-overlapping nanoclusters. 
Finally, promotion or inhibition of oncogenic K-Ras phosphorylation by PKC increased 
its co-clustering with the phosphomimetic or the non-phosphorylatable mutant, 
respectively. Most interestingly, PI3K (p110α) was found in phosphorylated and 
excluded in non-phosphorylated K-Ras nanoclusters. In conclusion, our data provide for 
the first time evidences that phosphorylation of oncogenic K-Ras by PKC induces 
segregation of K-Ras in spatially distinct nanoclusters at the plasma membrane which in 
turn would favor Raf-1 and PI3K activation.  
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INTRODUCTION 
Somatic activating Ras mutations are detected in about 15 to 20% of all human 
malignancies highlighting the importance of Ras GTPase-mediated signaling pathways 
in oncogenesis. These mutations, which give rise to a protein that is defective for GTP 
hydrolysis and, therefore, remains constitutively active in a GTP-bound form, have been 
detected in each of the three closely related human Ras genes (Hras, Nras, and Kras). 
However, the vast majority of mutations detected in human cancers arise in the K-Ras 
gene (Prior et al., 2012;Pylayeva-Gupta et al., 2011;Schubbert et al., 2007). 
H- and N-Ras achieve high-affinity hydrophobic membrane binding mainly through 
lipid modifications. In contrast, K-Ras has, adjacent of the farnesylated cysteine, a 
stretch of lysine residues- known as the polybasic domain - which promotes an 
electrostatic interaction with the negatively-charged phospholipids (Hancock et al., 
1989;Silvius, 2002) confining K-Ras almost entirely to non-raft plasma membrane 
microdomains (Prior et al., 2001) 
The different membrane anchors interact with lipids and proteins of the plasma 
membrane and together with the hypervariable region (HVR), drive the Ras isoforms 
into spatially and structurally distinct nanodomains, each one containing a cluster of 
molecules (nanocluster) (Abankwa et al., 2008;Hancock and Parton, 2005).  
Importantly, the nanodomains occupied by the three isoforms of Ras do not show any 
overlap. Interestingly, not only are the different Ras isoforms laterally segregated, but 
inactive GDP-loaded Ras occupies nanodomains that are spatially distinct from those 
occupied by the active GTP-loaded form, indicating that the globular domain of the 
protein also regulates the interaction with the distinct membrane nanodomains. The 
formation of these nanoclusters is essential for the mitogen-activated protein kinase 
(MAPK) activation as they constitute the exclusive sites for Raf-1 recruitment and ERK 
activation in the plasma membrane (Kholodenko et al., 2010;Plowman et al., 2005;Tian 
et al., 2007)  
As electrostatic interactions control the membrane interaction process for K-Ras, 
membrane affinity can be modulated by changes in the overall charge of the polybasic 
domain via Ser181 phosphorylation (Ahearn et al., 2011;Ballester et al., 1987;Bivona et 
al., 2006;Plowman et al., 2008). In a recent work we demonstrated that Ser181-
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phosphorylation regulates both wild-type and oncogenic K-Ras functions. Focus 
formation capacity, mobility and apoptosis resistance upon adriamycin treatment of 
cells expressing oncogenic non-phosphorylatable K-Ras were highly compromised, 
correlating with a decreased activation of main downstream effectors ERK and AKT. 
Therefore, in our model, K-Ras phosphorylation is essential to ensure a proper 
activation of ERK and AKT pathways with an important functional relevance (Alvarez-
Moya et al., 2010;Alvarez-Moya et al., 2011). 
Understanding how phosphorylation modulates oncogenic K-Ras activity is of 
outstanding interest to design new therapeutic strategies against human carcinomas with 
oncogenic K-Ras mutations. Here we show, using both, cell fractionation and immuno-
electron microscopy techniques, a segregation of oncogenic K-Ras at the plasma 
membrane according to its phosphorylation status with a potentials impact in effectors 
activation. We propose that this differential localization can be responsible for the 
distinct functionality of phosphorylated versus non-phosphorylated K-Ras.  
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RESULTS AND DISCUSSION 
Oncogenic K-Ras phosphorylation at Ser181 favors interaction with active Raf-1 
and PI3K catalytic subunit.  
We previously showed that phosphorylation of oncogenic K-RasG12V (always GTP-
loaded) at Ser181 was positively modulating ERK and AKT activation, especially under 
stress conditions. However, the in vitro affinity between oncogenic K-RasG12V and 
Raf-1 was not affected by this post-translational modification of K-Ras (Alvarez-Moya 
et al., 2010), and consequently, it could not explain the differences in ERK activation. 
Similarly, and in agreement with (Plowman et al., 2008), FRET analysis did not show 
an increase in the association of phosphomimetic oncogenic K-Ras (Ser181 mutated to 
Asp, named K-RasG12V-S181D) with Raf-1 compared to the non-phosphorylatable 
oncogenic K-Ras (Ser181 mutated to Ala, hereinafter referred to as K-RasG12V-
S181A) (Fig 1A and B).  Interestingly, although interaction of Raf-1 with K-Ras was 
not affected by the phosphorylation status of K-Ras, immunofluorescence analysis 
showed that a higher proportion of Raf-1 colocalizing with K-RasG12V-S181D was 
active, as show by Raf-1 phosphorylation at Ser338 (Fig. 1C and D). 
Co-immunoprecipitation analysis corroborated these results. While, the amount of Raf-1 
co-immunoprecipitated with non-phosphorylatable oncogenic K-Ras or with 
phosphomimetic K-Ras was not significantly different, K-RasG12V-S181D shows an 
increased ability to co-immunoprecipitate with active Raf-1 (P-Ser338). Finally, another 
K-Ras effector, the catalytic subunit of PtdIns-3 kinase (PI3K), p110α, also showed a 
higher co-immunoprecipitation with K-RasG12V-S181D than with K-RasG12V-S181A 
(Fig. 1E). Thus, we hypothesize that Ser181 phosphorylation of oncogenic K-Ras favors 
activation or retention of activated effectors, through a yet undefined mechanism. 
 
Differential fractionation of phosphorylated and not phosphorylated oncogenic K-
Ras at the plasma membrane. 
The negative charges introduced in the HVR by phosphorylation might modify the 
plasma membrane affinity of K-Ras and alter its localization (Yeung et al., 2006). In 
fact, certain groups have reported that phosphomimetic K-Ras is internalized to 
intracellular membranes such as mitochondria, Golgi apparatus, endoplasmic reticulum 
or endosomes (Bivona et al., 2006; Fivaz and Meyer, 2005). In contrast we show here 
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that after simultaneous transfection of both YFP-K-RasG12V-S181A and mCherry-K-
RasG12V-S181D in HEK293 cells, both phosphomutants were mainly located at the 
plasma membrane (Fig. 2A), in agreement with previous observations (Lopez-Alcala et 
al., 2008;Plowman et al., 2008). We aimed to analyze whether differential localization 
within the plasma membrane of phosphorylated versus non-phosphorylated K-Ras could 
be the basis for the observed differential active Raf-1 and PI3K recruitment. 
We aimed to test whether Ser181 phosphorylation of K-Ras could induce its segregation 
into different plasma membrane domains by performing a cell fractionation in a density 
gradient. K-Ras, in contrast to N- and H-Ras, is mainly localized in disordered non-raft 
detergent-sensitive plasma membrane domains (Prior et al., 2001). This constitutes a 
drawback when studying its distribution using the classical cell fractionation 
procedures. In our study, membranes from HEK293 cells were fractionated into a 
detergent free method to prevent the disruption of K-Ras domains was used(Macdonald 
and Pike, 2005), .  As cells were co-transfected with the two K-Ras mutants (YFP-K-
RasG12V-S181A and mCherry-K-RasG12V-S181D), a single fractionation and a single 
gel electrophoresis was performed per experiment, avoiding possible variability in 
gradient generation or gel loading. 
The early endosome marker, EEA1, the endoplasmic reticulum marker, Sec61α, and the 
caveolar lipid raft marker, Caveolin-1, were confined in the higher density fractions, in 
contrast, Na+/K+ ATPase distribution was extended throughout many fractions (Fig. 
2B),. Endogenous K-Ras (wild type) was always found between fractions 4 and 6 (Fig. 
2B,C,D,E). Furthermore, both exogenous non-oncogenic (wild-type) YFP-K-Ras and 
mCherry-K-Ras were found mainly in the same fractions as endogenous wild type K-
Ras (Fig S1). When analyzing the exogenous co-expressed oncogenic K-Ras 
phosphomutants, although a more spread distribution of the protein was observed 
compared to the endogenous K-Ras we reproducibly observed that non-
phosphorylatable K-Ras mutant (K-RasG12V-S181A) peaked  between fractions 5-7 
while the peak of phosphomimetic K-Ras (K-RasG12V-S181D) shifted towards the 
higher density fractions 8-10 (Fig- 2B,C,D). A prospective tag-artifact in the differential 
fractionation was dismissed because when the reverse tagged proteins were used 
(mChery-K-RasG12V-S181A and YFP-K-RasG12V-S181D), differences of 
fractionation according to the phosphorylation status were maintained (Fig. 2D and Fig. 
S1).  In agreement with data shown in figure 1B, both p110 α and phospho-Ser338-Raf-
1 exhibited higher co-fractionation with K-RasG12V-S181D rather than with the non-
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phosphorylatable K-Ras (Fig. 2B). This reinforces the concept of a segregated 
membrane domain for the phospho-S181-K-Ras that constitutes a preferential signaling 
platform. 
We next analyzed the localization of the phosphorylatable oncogenic K-Ras, (K-
RasG12V-S181). As shown in Fig. 2E, the majority of K-RasG12V-S181 was found at 
the beginning of the gradient while a certain amount fractionated together with K-
RasG12V-S181D, suggesting that a proportion of K-RasG12V-S181 is phosphorylated 
under these conditions.  
 
Segregation of phosphorylated and non-phosphorylated oncogenic K-Ras in non-
overlapping clusters at the plasma membrane.  
In order to further determine the presence of distinct segregated phosho-Ser181-K-Ras 
nanodomains that ensure preferential signaling platforms, we attempted to analyze the 
distribution at the nanoscale level of our oncogenic K-Ras phosphomutants. Analysis of 
gold-labeled protein distribution using a combined immune-EM-statistics approach 
allows the characterization of K-Ras nanoclusters in otherwise morphologically 
featureless plasma membrane (Prior et al., 2003). Furthermore it has also been shown 
that both phosphorylated and non-phosphorylatable K-Ras are able to form such 
nanoclusters (Plowman et al., 2008). Since our fractionation experiments indicate 
segregation of phosphorylated and non-phosphorylatable K-Ras and the inner leaflet of 
the plasma membrane consists of a mosaic of different nanoclusters (Prior et al., 2003), 
we wanted to directly compare nanocluster distributions of our K-Ras variants. To this 
end, cells were co-transfected with both oncogenic K-Ras phospho-mutants fused to 
either YFP or mCherry. Intact 2D sheets of apical plasma membrane were ripped off 
from adherent cells directly onto electron microscopy grids and immunogold labeled 
using anti-GFP antibodies conjugated directly to 5 nm gold particles and anti-RFP 
antibodies directly conjugated to 10 nm gold particles.  To estimate the degree of co-
clustering between our K-RasG12V species the Ripley’s bivariate K-function was used. 
As a positive control, co-transfection of the same mutant with different tags was 
performed to assess if co-clustering could be observed. As expected, YFP-K-RasG12V-
S181D co-clustered with mCherryK-RasG12V-S181D, thus dismissing the possibility 
of a tag-effect. In contrast, if cells were co-transfected with YFP-K-RasG12V-S181D 
and mCherryK-RasG12V-S181A no co-clustering was observed, providing striking 
evidences that confirm our initial conception of the existence of a spatially segregated 
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cluster for phospho-K-RasG12V (Fig. 3A,D). In agreement with Plowman et al 
(Plowman et al., 2008), the analysis of clusters using the Ripley’s univariate K-function 
in the same samples, showed that both non-phosphorylatable K-Ras and 
phosphomimetic K-Ras were able to form clusters (data not shown).  
Protein Kinase C (PKC) can phosphorylate K-Ras in vitro (Ballester et al., 1987), and it 
has been shown in vivo that phosphorylation of Ser181 is induced under conditions of 
PKC activation (PMA) and CaM inhibition (W13) while reduced after treatment with 
PKC inhibitors (BIM) (Alvarez-Moya et al., 2010). To conclusively demonstrate that 
Ser181 phosphorylation was regulating the localization of oncogenic K-Ras in different 
nanoclusters at the plasma membrane, co-clustering of K-RasG12V-S181 with K-
RasG12V-S181D and with K-RasG12V-S181A was analyzed after phosphorylation 
induction (PMA+W13) or phosphorylation inhibition (BIM), using the immuno-EM-
statistics approach indicated above ( Fig. 3B,D).  
 
Clustering of  PI3K-p110α with phosphorylated K-Ras 
To analyze the functional significance of the different clustering of oncogenic K-Ras 
according to its phosphorylation status, the above immuno-EM-statistics approach was 
used again.  Cells were co-transfected with mGFP-p110α and mCherryK-RasG12V-
S181D or mCherryK-RasG12V-S181A, and processed as indicated in the previous 
section. Ripley’s bivariate K-function showed a strong co-clustering of mGFP-p110α 
with the phosphomimetic K-Ras mutant, while excluding distribution was observed 
with the non-phophorylatable K-Ras. Finally, co-clustering analysis of mGFP-p110α 
with phosphorylatable K-Ras after phosphorylation induction (PMA+W13) or inhibition 
(BIM), conclusively demonstrated that PI3K-p110α is efficiently recruited to the 
phosho-K-Ras segregated clusters (Fig 3C,D). 
 
 
Through an integrated approach of density gradient fractionation and immuno-EM-
statistics, we have found striking evidence of oncogenic K-Ras lateral segregation in the 
inner leaflet of plasma membrane by means of phosphorylation at Ser181 with a 
functional significance. We demonstrated that phosphorylated K-Ras exhibits a higher 
association with active c-Raf1 and PI3K (p110α), and at the nanoscale, it clusters 
together with PI3K (p110α). Since nanoclusters operate as temporary signaling 
platforms at the plasma membrane which contain certain mixtures of kinases, 
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phosphatases and other signaling proteins (Inder et al., 2008;Prior et al., 2003), 
molecular environment facilitating activation of major K-Ras effectors is expected to be 
found in the phospho-K-Ras platforms (Fig. 4). Our findings provide a novel rationale 
to explain how oncogenic K-Ras molecules, which are always GTP-loaded and thus 
presumably active, exhibit a differential signaling after phosphorylation. 
 
 
 
MATERIALS AND METHODS 
Cell culture  
Human Epithelial Kidney cell lines (HEK293T) and HeLa cell lines were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% FBS (Biological 
Industries), pyruvic acid, antibiotics, and glutamine.  
Antibodies and reagents 
Primary antibodies: Anti-Raf-1 (#610152; BD Transduction Laboratories, San Jose, 
CA); Anti-phospho-Ser338-Raf-1 (#05534;Millipore, Billerica, MA, USA) ; Anti- 
PI3Kinase p110α (clone C73F8) (#4249; Cell Signalling, Danvers, MA, USA); Anti-
HA (clone HA-7) (#A2095; Sigma, St. Louis, MO, USA); Anti-RFP rabbit (#A01388-
40; GenScript, Piscataway, NJ, USA); Anti-GFP mouse (#ADI-SAB-500-E; 
Stressgene); Anti-K-Ras (Ab-1) (#OP24; Calbiochem); Anti-H-Ras (C-20) (#sc-520, 
Santa Cruz, Santa Cruz, CA, USA), Anti-Na+/K+-ATPase (clone C464.6) (#05-369X-
555; Millipore); Anti-EEA1 (#610457; BD Bioscience, Franklin Lakes, NJ USA); Anti-
Sec61α (#07-204; Millipore); Anti-Cav1 (#610407; BD Bioscience).  
PMA (phorbol-12-myristate-13-acetate)  and  W13 (N-(4-aminobutyl)-5-cloro-2-
naphtalensulphonamide) were from  Sigma, (St. Louis, Mo, USA) and BIM 
(bisindolylmaleimide) From Calbiochem.  
Immunoprecipitation 
HeLa cells (1 x 100-cm dish) co-transfected with myc-Raf-1 and either HA-K-
RasG12V-S181A or HA-K-RasG12V-S181D by X-tremeGENE HP DNA Transfection 
Reagent (Roche) were lysed in  Ras extraction buffer (Alvarez-Moya et al. ,2010) and 
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the lysate incubated for 3h at 4ºC with HA-tag antibody crosslinked to Dynabeads, 
washed 3 times and eluted with glycine 200 mM pH2,5. 
Confocal  Microscopy 
To determine mCherry-RasG12V-S181D and YFP-K-RasG12V-S181A colocalization, 
YFP and mCherry images were acquired sequentially using 514 and 561 laser lines, 
emission detection ranges 525-573 nm and 580-700 nm respectively and the confocal 
pinhole set at 1 Airy units. Images were acquired at 400 Hz in a 1024 x 1024 pixels 
format, zoom at 4 and pixel size of 60 x 60 nm. 
FRET measurements were based on the acceptor photobleaching method and performed 
as previously decribed (Vila de la Muga et al. 2009).  
 
Density gradient 
 HEK293T cells (7x150 cm dish plates) were transfected by Calcium Phosphate and 
after  24-48h cell membrane fractionation into a continuous OptiPrep density gradient 
was performed as previously described (Macdonald and Pike, 2005) with the exception 
of the densities used (sample at 20% and continuous gradient from 15% to 0% (v/v)) 
Gradients were fractionated into 670 µL fractions.,  
High-resolution analysis of plasma membrane K-Ras clustering 
HeLa cells were grown on coverslips at low density and co-transfected either with YFP- 
or mCherry- K-RasG12V, K-RasG12V-S181A, K-RasG12V-S181D; or with GFP-
p110α and mCherry- K-RasG12V, K-RasG12V-S181A or K-RasG12V-S181D by 
GeneJuice (Merck Millipore) according to the manufacturer's specifications. After 24h 
of transfection cells were fixed in 4% paraformaldehyde plus 0.1% glutaraldehyde, and 
labeled with gradient-purified 2nm- and 5nm-conjugated antibodies, as previously 
described (Prior et al., 2003). Plasma membrane sheets were imaged using an FEI 
120kV Tecnai transmission electron microscope obtaining images at 87,000 x 
magnification. Image processing and Bivariate K-Ripley Function analysis was 
performed to examine whether either gold particle population, at a distance r, is 
clustered around the other. Significance test of Bivariate K-Ripley Function were 
performed by Monte Carlo methods as described (Prior et al., 2003).  
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FIGURES LEGENDS 
 
Fig 1. Differential interaction of oncogenic K-Ras with phospho-Ser338- Raf-1 and 
catalytic subunit of PI3K according to K-Ras Ser181 phosphorylation status. (A) 
HeLa cells co-expressing YFP-Raf-1 and Cer-K-RasG12V-S181A or Cer-K-RasG12V-
S181D were measured using acceptor photobleaching FRET microscopy. Corrected 
FRET is presented as a quantitative pseudocolor image (right column); (B) The graph 
shows corrected FRET efficiency ± SEM  from (A); (C) Cells as in (A) were stained 
with anti-phospho-Ser-338-Raf-1 and incubated with Alexa647-labeled secondary 
antibody. Corrected P-Raf-1 efficiency is presented as a quantitative pseudocolor image 
(right column); (D) Quantification of Raf-1 Ser338-phosphorylation efficiency (P-Raf-
1/Raf-1) from (C); (E) HeLa cells were co-transfected with both myc-Raf-1 and either 
HA-K-RasG12V-S181A (non-phosphorylatable) or HA-K-RasG12V-S181D 
(phosphomimetic).  Cell lysates were immunoprecipitated with anti-HA antibody or 
mouse IgG (IgG) and the input and the bound fractions were immunoblotted with the 
indicated antibodies. (***, p<0.0001, **p<0.001 and *p<0. 01, p value for Student’s 
two-tailed t test; ns: non-significant differences; mean and SEM are represented).  
 
Fig 2. Separation of oncogenic K-Ras according to its phosphorylation status into 
different density fractions. (A) HEK 293 cells were co-transfected with the indicated 
pairs of K-Ras phosphomutants and localization analyzed by confocal microscopy. 
(B,C,D,E) HEK293 cells co-transfected with the indicated constructs were lysed in a 
detergent-free method and post-nuclear supernatant was fractionated into an Optiprep 
gradient fraction.  (B) Phosphomutants and membrane markers distribution from 
HEK293 cells co-transfected with YFP-K-RasG12V-S181A/mCh-K-RasG12V-S181D 
was analyzed by western blotting. (C) Quantification of phosphomutants and 
endogenous K-Ras along the generated Optiprep gradient fractions from panel B (left). 
Distribution of both Optiprep and protein concentration (right). (D) A possible tag-
effect was discarded by exchanging the tags of the phosphomutants (YFP-K-RasG12V-
S181D/mCh-K-RasG12V-S181A) and performing the same fractionation as in (B). (E) 
Partial overlapping of wild type-Ser181 mCh-K-RasG12V with phosphomimetic YFP-
K-RasG12V-S181D  
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Fig  3. Spatial segregation of oncogenic K-Ras into functionaly different non-
overlapping nanodomains according to Ser181 phosphorylation.. (A) HeLa cells 
were co-transfected with the pairs YFP-K-RasG12V-S181D/mCh-K-RasG12V-S181D 
to study a possible tag-effect when performing the analysis and with YFP-K-RasG12V-
S181D/mCh-K-RasG12V-S181A to estimate clustering overlapping. (B) HeLa cells 
were co-transfected with the pairs YFP-K-RasG12V-S181D/mCh-K-RasG12V-S181 
and after 24h of expression were either left untreated (control, blue line), serum starved 
for 6h and treated with 100 nM PMA + 15 µg/ml W13 for 30 min (to promote K-Ras 
phosphorylation, red line), or treated with 5µM BIM for 1h (to inhibit PKC, green line). 
(C) HeLa cells were co-transfected with the pairs mCh-K-RasG12V-S181D/EGFP-
p110α or mCh-K-RasG12V-S181A/EGFP-p110α to estimate clustering overlapping 
(left panel). HeLa cells were co-transfected with mCh-K-RasG12V/EGFP-p110α and 
treated as in (B) to either promote (PMA+W13) or prevent (BIM) K-Ras 
phosphorylation. In (A), (B) and (C), CI means confidence interval (values above this 
line indicate co-clustering).  (D) Examples of EM immunogold images used to perform 
analysis shown I (A), (B) and (C).   
 
Fig 4. Model for the spatial segregation of oncogenic K-Ras by Ser181 
phosphorylation.  (A) Schematic representation of K-Ras structure showing the 
composition of the wildtype and phosphomutants C-terminal polybasic domains. 
Positively-charged residues (blue), negatively-charged (red), non-charged (black). (B) 
Image showing real localization of K-Ras molecules (from Fig. S2) and speculative 
distribution of active K-Ras effectors. Upon Ser181 phosphorylation, oncogenic K-Ras 
molecules migrate to spatially distinct non-raft nanodomains forming non-overlapping 
nanoclusters or, alternatively, phosphoryation is induced a preexisting nanocluster. 
Phospho-Ser181-K-RasG12V nanoclusters serves as preferential signaling platforms for 
the activation of main K-Ras effectors.  
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